内容紹介
A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin
Summary
A 57-year-old multiparous woman with FIGO stageⅣ ovarian cancer underwent primary surgery and was administered postoperative chemotherapy consisting of paclitaxel and carboplatin(TC). Complete response was confirmed on computed tomography. After a 20-month platinum free interval(PFI), an elevated serum CA125 level and recurrence in the peritoneum were confirmed, and she was retreated with TC as second-line chemotherapy. A hypersensitivity reaction occurred after administering the second dose of carboplatin; therefore, carboplatin was changed to nedaplatin. Complete response was confirmed on computed tomography, and the serum CA125 level returned to normal. After an 8-month PFI, an elevated serum CA125 level and recurrence in the peritoneum and liver were confirmed, and she was treated with 6 cycles of combination chemotherapy consisting of gemcitabine(1,000 mg/m2: day 1 and 8 q3weeks)and nedaplatin(80 mg/m2: day 1 q3 weeks). Only cytopenia(grade 2: CTCAE v4.0)was noted as a complication during chemotherapy. Complete response was confirmed on computed tomography. This report presents the case of a patient with recurrent ovarian cancer who was platinum sensitive and successfully treated with gemcitabine and nedaplatin after showing a hypersensitivity reaction to carboplatin.
要旨
症例は57歳,女性。2経妊1経産。卵巣癌Ⅳ期の診断で手術を施行するも完全切除は不可能で,術後paclitaxel(PTX)+carboplatin(CBDCA): TC療法を6サイクル施行しcomplete response(CR)となった。platinum free interval(PFI)20か月で再発し,再度TC療法を施行するも2サイクル目のCBDCA投与で過敏性反応を認め投与中止した。PTX+nedaplatin(NDP)へレジメンを変更,計6サイクル施行しCRを得た。その後PFI 8か月で再再発。third-lineとしてgemcitabine(GEM)+NDP: GN療法を6サイクル施行しCRを得られた。発生した有害事象はgrade 2の白血球減少のみであった(CTCAE v4.0)。CBDCA過敏性反応を示したプラチナ感受性再発卵巣癌に対するGN療法の有用性が示唆された。
目次
Summary
A 57-year-old multiparous woman with FIGO stageⅣ ovarian cancer underwent primary surgery and was administered postoperative chemotherapy consisting of paclitaxel and carboplatin(TC). Complete response was confirmed on computed tomography. After a 20-month platinum free interval(PFI), an elevated serum CA125 level and recurrence in the peritoneum were confirmed, and she was retreated with TC as second-line chemotherapy. A hypersensitivity reaction occurred after administering the second dose of carboplatin; therefore, carboplatin was changed to nedaplatin. Complete response was confirmed on computed tomography, and the serum CA125 level returned to normal. After an 8-month PFI, an elevated serum CA125 level and recurrence in the peritoneum and liver were confirmed, and she was treated with 6 cycles of combination chemotherapy consisting of gemcitabine(1,000 mg/m2: day 1 and 8 q3weeks)and nedaplatin(80 mg/m2: day 1 q3 weeks). Only cytopenia(grade 2: CTCAE v4.0)was noted as a complication during chemotherapy. Complete response was confirmed on computed tomography. This report presents the case of a patient with recurrent ovarian cancer who was platinum sensitive and successfully treated with gemcitabine and nedaplatin after showing a hypersensitivity reaction to carboplatin.
要旨
症例は57歳,女性。2経妊1経産。卵巣癌Ⅳ期の診断で手術を施行するも完全切除は不可能で,術後paclitaxel(PTX)+carboplatin(CBDCA): TC療法を6サイクル施行しcomplete response(CR)となった。platinum free interval(PFI)20か月で再発し,再度TC療法を施行するも2サイクル目のCBDCA投与で過敏性反応を認め投与中止した。PTX+nedaplatin(NDP)へレジメンを変更,計6サイクル施行しCRを得た。その後PFI 8か月で再再発。third-lineとしてgemcitabine(GEM)+NDP: GN療法を6サイクル施行しCRを得られた。発生した有害事象はgrade 2の白血球減少のみであった(CTCAE v4.0)。CBDCA過敏性反応を示したプラチナ感受性再発卵巣癌に対するGN療法の有用性が示唆された。